

# Clinical Policy: Gastric Electrical Stimulation

Reference Number: PA.CP.MP.40

Effective Date: 01/18

Last Review Date: 10/17

[Coding Implications](#)

[Revision Log](#)

## Description

Gastric electrical stimulation (GES) has been used in patients who are proven refractory to conventional treatment for gastroparesis. It can be used as an alternative to surgery to reduce some symptoms of gastroparesis. Electrodes that are surgically or endoscopically attached to the stomach wall deliver timed electrical impulses to trigger stomach contractions. This stimulation has not shown a significant improvement in gastric emptying, but has shown to benefit those with nausea and vomiting as their main symptoms.

## Policy/Criteria

- I.** It is the policy of Pennsylvania Health and Wellness<sup>®</sup> (PHW) that GES is **medically necessary** for diabetic and idiopathic gastroparesis when all of the following criteria are met:
- A. Severe nausea and vomiting occurs on most days of the week for the duration of  $\geq 1$  year, *and*
  - B. Documented intolerance or failure to a trial of antiemetic and prokinetic drug therapy;
  - C. Does not have any of the following contraindications:
    - 1. Pregnancy;
    - 2. Chemical dependency;
    - 3. Undergoing peritoneal dialysis;
    - 4. Diagnosis of cancer with a limited estimated life span.

*Note:* Current recommended combination prokinetic therapy includes metoclopramide and erythromycin.

**II.** It is the policy of PHW that GES is **not medically necessary** for reduction in pain, fullness, bloating, or acid reflux symptoms as there is no evidence to support efficacy of such therapy.

**III.** It is the policy of PHW that GES is **investigational** for the treatment of obesity due to a lack of evidence in the peer review literature demonstrating the long term safety and efficacy of this device.

## Background

### *Gastric Electrical Stimulation for Gastroparesis*

Gastroparesis is a disorder in which there is delayed gastric emptying following ingestion of food, in the absence of mechanical obstruction, due to abnormal or absent motility of the stomach. The stomach is unable to contract normally, and therefore cannot crush food nor propel food into the small intestine properly.

Approximately two-thirds of cases are idiopathic or associated with diabetes mellitus, but gastroparesis may also develop after gastric surgery and in other less common conditions. The main symptoms include nausea, vomiting, early satiety, bloating, and discomfort. Nausea and vomiting may be so severe that they cause weight loss, dehydration, electrolyte disturbances, and malnutrition.

## CLINICAL POLICY

### Gastric Electrical Stimulation

It is theorized that GES works in the following ways:

1. Activation of the central mechanisms for nausea and vomiting control related to afferent nerves being stimulated by the constant high frequency current in the stomach wall.
2. Enhanced relaxation of the fundus of the stomach by this current thus providing better accommodation and decreased sensitivity to distention.
3. Augmentation of the amplitude of gastric slow wave after eating.
4. Increase in cholinergic function and decreased sympathetic functions
5. Small and unpredictable improvements in gastric emptying.

The results of a number of studies have shown an improvement in quality of life score, even though on average, gastric emptying did not change. Quality of life scores improved along with a decrease in hospital admission days, reduction in hemoglobin A1C, and weight gain. Nausea and vomiting have also showed improvements for at least one year after surgery.

#### *Gastric Electrical Stimulation for Obesity*

GES is currently under investigation as a treatment for obesity. Cha et al. (2014) reviewed current approaches to evaluate the effect GES on obesity. 31 studies were included in their systematic review. Although most of the studies showed weight loss in the treatment group, most had a follow-up duration of 12 months or less. Some of the evaluated GES treatments also showed positive effects in lowering HbA1c and blood pressure.<sup>9</sup> Cha et al. stated that GES holds great promise for the treatment of obesity, but stronger studies with longer follow-up are needed to determine long-term effects.<sup>9</sup> Lebovitz (2016) reviewed the evidence on three different methods of GES, including the Transcend<sup>®</sup> Implantable Gastric Stimulator, the Maestro<sup>™</sup> vagal blockade device, and the DIAMOND<sup>™</sup> gastric electrical stimulatory device.<sup>10</sup> Two randomized controlled trials failed to show a significant benefit in excess weight loss with the Transcend device.<sup>10</sup> The other evaluated GES device, the DIAMOND, has been assessed in clinical trials with obese patients with type 2 diabetes. Findings were positive but varied among the patients included in treatment. Effects included reduced HbA1c and weight loss, and seemed to be influenced by baseline HbA1c levels and triglyceride levels.<sup>10</sup> Further research is needed to determine long-term effects and appropriate patient selection criteria to ensure the best outcomes.

#### **Coding Implications**

This clinical policy references Current Procedural Terminology (CPT<sup>®</sup>). CPT<sup>®</sup> is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2015, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are for informational purposes only. They are current at time of review of this policy. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT <sup>®*</sup> Codes	Description
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open

**CLINICAL POLICY**  
**Gastric Electrical Stimulation**



CPT®* Codes	Description
64590	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling
64595	Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver

\*CPT Copyright 2015 American Medical Association. All rights reserved.  
 CPT is a registered trademark of the American Medical Association.

HCPCS Codes	Description
E0765	FDA approved nerve stimulator with replaceable batteries for nausea and vomiting

**ICD-10-CM Diagnosis Codes that Support Coverage Criteria**

ICD-10-CM Code	Description
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly) neuropathy
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly) neuropathy
E10.43	Type I diabetes mellitus with diabetic autonomic (poly) neuropathy
E11.43	Other specified diabetes mellitus with diabetic autonomic (poly) neuropathy
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly) neuropathy
K31.84	Gastroparesis

Reviews, Revisions, and Approvals	Date	Approval Date

**Bibliography**

1. Abell TL, et al. Gastric electrical stimulation in intractable symptomatic gastroparesis. *Digestion; International Journal of Gastroenterology*, (2002) 66:4.
2. Abell T, et al. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up. *Journal of Parenteral and Enteral Nutrition*, (2003) 27:4, 277-281. <http://pen.sagepub.com/cgi/content/abstract/27/4/277>
3. Camilleri M, et al. Clinical guideline: Management of gastroparesis. *Am J Gastroenterol*. 2013; 108: 18–37.
4. Forster J, et al. Further experience with gastric stimulation to treat drug refractory gastroparesis. *The American Journal of Surgery*, December 2003, 186:6, 690-695.
5. Fox J, Foxx-Orenstein A. *Gastroparesis*. Mayo Clinic Rochester. Accessed August 04, 2010 at: <http://www.acg.gi.org/patients/gihealth/pdf/gastroparesis.pdf>
6. Hayes Medical Technology Directory. Gastric electrical stimulation for gastroparesis. November 21, 2014.

## CLINICAL POLICY

### Gastric Electrical Stimulation

7. Hasler, WL. Electrical stimulation for gastroparesis. In: UpToDate, Talley, NJ (Ed), UpToDate, Waltham, MA. Accessed 10/10/2016.
8. Parkman HP, Fass R, Foxx-Orenstein AE. Treatment of patients with diabetic gastroparesis. *Gastroenterol Hepatol (N Y)*. 2010 June; 6(6 Suppl 9): 1–16.
9. Cha R, Marescaux J, Diana M. Updates on gastric electrical stimulation to treat obesity: Systematic review and future perspectives. *World J Gastrointest Endosc*. 2014 Sep 16;6(9):419-31.
10. Lebovitz HE. Interventional treatment of obesity and diabetes: An interim report on gastric electrical stimulation. *Rev Endocr Metab Disord*. 2016 17: 73-80. DOI 10.1007/s11154-016-9350-